Chadwick Jeremy G sold $292K of KYMR
Chadwick Jeremy G (Chief Operating Officer) sold 3,730 shares of Kymera Therapeutics, Inc. (KYMR) at $78.36 ($0.29M total) on 2026-05-26 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it is more consistent with scheduled diversification/liquidity than with a new fundamental development.
Market read
Traders may monitor for patterns of insider activity, but this specific disclosure is unlikely to be a standalone catalyst.
What to watch
The sale size is modest relative to typical institutional flows, and the 10b5-1 structure suggests routine liquidity rather than information.
Background
The article is an SEC Form 4 insider transaction disclosure for Kymera Therapeutics, reported by an officer (COO).
Ticker impact
Kymera Therapeutics COO Chadwick Jeremy G sold $292K of KYMR shares via an open-market transaction under a pre-arranged 10b5-1 plan.
Likely limited near-term impact; any move is more likely driven by broader biotech sentiment than this specific Form 4.
The filing specifies a pre-arranged 10b5-1 plan, which generally reduces the likelihood that the sale reflects new negative information.
Market effects
Minimal; single insider 10b5-1 sale rarely changes sector risk appetite.
None indicated.
None indicated.
Counterpoint
Some traders may still view insider selling as a mild cautionary signal, especially if multiple recent insider sales cluster.
Key entities
- issuerKymera Therapeutics, Inc.
Subject of the Form 4 insider transaction; COO sold 3,730 shares for ~$292K under a 10b5-1 plan.
- insiderChadwick Jeremy G
COO who executed the open-market sale disclosed in the Form 4.
